Abhishek Shenoy,Venkata Sai Jasty,Sarah Uttal,Sarah Nasser,Gerald Scott Winder,Jessica Mellinger,Robert J Fontana
{"title":"治疗酒精使用障碍的药物越来越多地被用于美国晚期肝病患者。","authors":"Abhishek Shenoy,Venkata Sai Jasty,Sarah Uttal,Sarah Nasser,Gerald Scott Winder,Jessica Mellinger,Robert J Fontana","doi":"10.14309/ajg.0000000000003328","DOIUrl":null,"url":null,"abstract":"The number of alcohol use disorder patients with mild (n=101) and severe alcoholic liver disease (n=112) increased between 2013 and 2023 (p=0.06). Naltrexone was prescribed in 65%, acamprosate 26% and disulfiram 9%. Internal medicine providers were the most frequent prescribers (51%) followed by Psychiatry (30%), and GI/Hepatology (9%) (p=0.001). Duration of use was longest with naltrexone compared to acamprosate and disulfiram (360 vs 251 vs 190 days, p=0.032). The rate of AUD medication discontinuation for adverse events was similar in both groups (14% vs 12%). Naltrexone, acamprosate, and disulfiram are increasingly being prescribed in American patients with mild and severe ALD with similar tolerability and efficacy.","PeriodicalId":520099,"journal":{"name":"The American Journal of Gastroenterology","volume":"32 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Medications for Alcohol Use Disorder Are Increasingly Being Prescribed in American Patients with Advanced Liver Disease.\",\"authors\":\"Abhishek Shenoy,Venkata Sai Jasty,Sarah Uttal,Sarah Nasser,Gerald Scott Winder,Jessica Mellinger,Robert J Fontana\",\"doi\":\"10.14309/ajg.0000000000003328\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The number of alcohol use disorder patients with mild (n=101) and severe alcoholic liver disease (n=112) increased between 2013 and 2023 (p=0.06). Naltrexone was prescribed in 65%, acamprosate 26% and disulfiram 9%. Internal medicine providers were the most frequent prescribers (51%) followed by Psychiatry (30%), and GI/Hepatology (9%) (p=0.001). Duration of use was longest with naltrexone compared to acamprosate and disulfiram (360 vs 251 vs 190 days, p=0.032). The rate of AUD medication discontinuation for adverse events was similar in both groups (14% vs 12%). Naltrexone, acamprosate, and disulfiram are increasingly being prescribed in American patients with mild and severe ALD with similar tolerability and efficacy.\",\"PeriodicalId\":520099,\"journal\":{\"name\":\"The American Journal of Gastroenterology\",\"volume\":\"32 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The American Journal of Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14309/ajg.0000000000003328\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14309/ajg.0000000000003328","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
2013年至2023年间，伴有轻度酒精性肝病（n=101）和重度酒精性肝病（n=112）的酒精使用障碍患者数量增加（p=0.06）。纳曲酮占65%，阿坎普罗酸占26%，双硫仑占9%。内科医生是最常见的开处方者（51%），其次是精神病学（30%）和胃肠病学/肝病学（9%）（p=0.001）。纳曲酮的使用时间比阿坎前列酸和双硫仑最长（360天、251天和190天，p=0.032）。两组患者因不良事件而停药的比例相似（14% vs 12%）。纳曲酮、阿坎普罗酸和双硫仑越来越多地被用于美国轻度和重度ALD患者，它们的耐受性和疗效相似。
Medications for Alcohol Use Disorder Are Increasingly Being Prescribed in American Patients with Advanced Liver Disease.
The number of alcohol use disorder patients with mild (n=101) and severe alcoholic liver disease (n=112) increased between 2013 and 2023 (p=0.06). Naltrexone was prescribed in 65%, acamprosate 26% and disulfiram 9%. Internal medicine providers were the most frequent prescribers (51%) followed by Psychiatry (30%), and GI/Hepatology (9%) (p=0.001). Duration of use was longest with naltrexone compared to acamprosate and disulfiram (360 vs 251 vs 190 days, p=0.032). The rate of AUD medication discontinuation for adverse events was similar in both groups (14% vs 12%). Naltrexone, acamprosate, and disulfiram are increasingly being prescribed in American patients with mild and severe ALD with similar tolerability and efficacy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
